RXRX – Recursion Pharmaceuticals, Inc.
RXRX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
36.52
Margin Of Safety %
Put/Call OI Ratio
0.23
EPS Next Q Diff
-0.01
EPS Last/This Y
0.52
EPS This/Next Y
0.04
Price
3.01
Target Price
6.64
Analyst Recom
2.25
Performance Q
-11.73
Upside
-618.3%
Beta
1.02
Ticker: RXRX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | RXRX | 3.51 | 0.26 | 0.12 | 353828 |
| 2026-04-24 | RXRX | 3.52 | 0.26 | 0.04 | 354779 |
| 2026-04-27 | RXRX | 3.48 | 0.27 | 0.06 | 350352 |
| 2026-04-28 | RXRX | 3.41 | 0.27 | 0.35 | 350870 |
| 2026-04-29 | RXRX | 3.31 | 0.27 | 0.42 | 352585 |
| 2026-04-30 | RXRX | 3.46 | 0.27 | 0.06 | 356402 |
| 2026-05-01 | RXRX | 3.38 | 0.27 | 0.05 | 359454 |
| 2026-05-04 | RXRX | 3.52 | 0.26 | 0.21 | 363285 |
| 2026-05-05 | RXRX | 3.38 | 0.26 | 0.76 | 369123 |
| 2026-05-06 | RXRX | 3.43 | 0.27 | 0.10 | 375152 |
| 2026-05-07 | RXRX | 3.28 | 0.27 | 0.09 | 372939 |
| 2026-05-08 | RXRX | 3.32 | 0.27 | 0.10 | 374063 |
| 2026-05-11 | RXRX | 3.27 | 0.27 | 0.04 | 356166 |
| 2026-05-12 | RXRX | 3.14 | 0.26 | 0.21 | 367090 |
| 2026-05-13 | RXRX | 3.05 | 0.26 | 0.18 | 369295 |
| 2026-05-14 | RXRX | 3.04 | 0.27 | 0.10 | 372264 |
| 2026-05-15 | RXRX | 2.92 | 0.26 | 0.21 | 374655 |
| 2026-05-18 | RXRX | 2.89 | 0.23 | 0.20 | 330660 |
| 2026-05-19 | RXRX | 2.86 | 0.23 | 0.17 | 333953 |
| 2026-05-20 | RXRX | 2.95 | 0.23 | 0.10 | 335189 |
| 2026-05-21 | RXRX | 3.12 | 0.23 | 0.07 | 337587 |
| 2026-05-22 | RXRX | 3.01 | 0.23 | 0.29 | 340214 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | RXRX | 3.51 | 50.0 | - | -0.95 |
| 2026-04-24 | RXRX | 3.51 | 50.0 | - | -0.95 |
| 2026-04-27 | RXRX | 3.49 | 50.0 | - | -0.95 |
| 2026-04-28 | RXRX | 3.41 | 50.0 | - | -0.95 |
| 2026-04-30 | RXRX | 3.46 | 50.0 | - | -0.95 |
| 2026-05-01 | RXRX | 3.38 | 50.0 | - | -0.95 |
| 2026-05-04 | RXRX | 3.52 | 48.5 | - | -1.01 |
| 2026-05-05 | RXRX | 3.38 | 48.5 | - | -1.01 |
| 2026-05-06 | RXRX | 3.44 | 48.5 | - | -1.01 |
| 2026-05-07 | RXRX | 3.27 | 48.6 | - | -1.01 |
| 2026-05-08 | RXRX | 3.33 | 48.6 | - | -0.90 |
| 2026-05-11 | RXRX | 3.27 | 45.4 | - | -0.90 |
| 2026-05-12 | RXRX | 3.14 | 45.3 | - | -0.90 |
| 2026-05-13 | RXRX | 3.05 | 43.5 | - | -0.90 |
| 2026-05-14 | RXRX | 3.03 | 43.5 | - | -0.90 |
| 2026-05-15 | RXRX | 2.92 | 43.5 | - | -0.93 |
| 2026-05-18 | RXRX | 2.89 | 43.5 | - | -0.93 |
| 2026-05-19 | RXRX | 2.86 | 43.5 | - | -0.93 |
| 2026-05-20 | RXRX | 2.95 | 43.5 | - | -0.93 |
| 2026-05-21 | RXRX | 3.11 | 43.5 | - | -0.93 |
| 2026-05-22 | RXRX | 3.01 | 43.5 | - | -0.92 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | RXRX | -2.42 | 2.50 | 37.27 |
| 2026-04-24 | RXRX | -2.52 | 2.50 | 37.27 |
| 2026-04-27 | RXRX | -2.37 | 2.45 | 37.37 |
| 2026-04-28 | RXRX | -2.37 | 2.45 | 37.37 |
| 2026-04-29 | RXRX | -2.37 | 2.45 | 37.37 |
| 2026-04-30 | RXRX | -2.37 | 2.45 | 37.37 |
| 2026-05-01 | RXRX | -2.37 | 2.45 | 37.37 |
| 2026-05-04 | RXRX | -2.37 | 0.54 | 37.37 |
| 2026-05-05 | RXRX | -2.37 | 0.54 | 37.37 |
| 2026-05-06 | RXRX | -2.37 | 0.54 | 37.37 |
| 2026-05-07 | RXRX | -2.31 | 0.54 | 37.37 |
| 2026-05-08 | RXRX | -2.35 | 0.54 | 37.37 |
| 2026-05-11 | RXRX | -2.41 | 0.57 | 37.18 |
| 2026-05-12 | RXRX | -2.41 | 0.57 | 36.52 |
| 2026-05-13 | RXRX | -2.41 | 0.57 | 36.52 |
| 2026-05-14 | RXRX | -2.41 | 0.57 | 36.52 |
| 2026-05-15 | RXRX | -2.41 | 0.57 | 36.52 |
| 2026-05-18 | RXRX | -2.41 | -0.14 | 36.52 |
| 2026-05-19 | RXRX | -2.41 | -0.14 | 36.52 |
| 2026-05-20 | RXRX | -2.35 | -0.14 | 36.52 |
| 2026-05-21 | RXRX | -2.35 | -0.14 | 36.52 |
| 2026-05-22 | RXRX | -2.35 | -0.14 | 36.52 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.22
Avg. EPS Est. Current Quarter
-0.23
Avg. EPS Est. Next Quarter
-0.23
Insider Transactions
-2.35
Institutional Transactions
-0.14
Beta
1.02
Average Sales Estimate Current Quarter
13
Average Sales Estimate Next Quarter
18
Fair Value
Quality Score
30
Growth Score
47
Sentiment Score
37
Actual DrawDown %
93
Max Drawdown 5-Year %
-93.1
Target Price
6.64
P/E
Forward P/E
PEG
P/S
24.06
P/B
1.56
P/Free Cash Flow
EPS
-1.2
Average EPS Est. Cur. Y
-0.92
EPS Next Y. (Est.)
-0.88
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-842.93
Relative Volume
1.01
Return on Equity vs Sector %
-81.7
Return on Equity vs Industry %
-66.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.07
EBIT Estimation
◆
RXRX
Healthcare
$3.01
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
42
Range 1M
24.5%
Sup Dist
2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
35.9%
EPS NY
5.3%
52W%
5.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+120.6% upside
Upside
+120.6%
Quality
30
Recursion Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 600
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
RXRX
Latest News
—
Caricamento notizie per RXRX…
stock quote shares RXRX – Recursion Pharmaceuticals, Inc. Stock Price stock today
news today RXRX – Recursion Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RXRX – Recursion Pharmaceuticals, Inc. yahoo finance google finance
stock history RXRX – Recursion Pharmaceuticals, Inc. invest stock market
stock prices RXRX premarket after hours
ticker RXRX fair value insiders trading